AGM Statement

RNS Number : 2898O

Cambridge Cognition Holdings PLC

27 May 2015

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

AGM Statement

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

As I outlined in our Preliminary Results statement our financial performance remains in line with market expectations.

The contribution from our clinical trials and academic businesses continued to grow in the first quarter.  In particular the enlarged US sales team offers an opportunity to enhance both clinical and academic sales in North America and we already have a healthy pipeline of contracts in the safety and tolerability trial space that we expect to convert over the remainder of the year.

The return to profitability in our clinical trials and academic businesses enables us to increase investment in our early stage healthcare technology business which bodes well for the future prospects of the Company.

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Geoff Nash/Simon Hicks		(Corporate Finance)
Malar Velaigam	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 

END

 

 

AGMPKADPABKDAPB